Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

Author： Kono Toru   Hata Taishi   Morita Satoshi   Munemoto Yoshinori   Matsui Takanori   Kojima Hiroshi   Takemoto Hiroyoshi   Fukunaga Mutsumi   Nagata Naoki   Shimada Mitsuo   Sakamoto Junichi   Mishima Hideyuki  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.6, 2013-12, pp. : 1283-1290

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

By Guo Ying   Jones Desiree   Palmer J.   Forman Arthur   Dakhil Shaker   Velasco Maria   Weiss Matthias   Gilman Paul   Mills G.   Noga Stephen   Eng Cathy   Overman Michael   Fisch Michael  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1223-1231

Springer Publishing Company

Access to resources Recommend Favorite

Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial

By Rastelli Antonella   Taylor Marie   Gao Feng   Armamento-Villareal Reina   Jamalabadi-Majidi Shohreh   Napoli Nicola   Ellis Matthew  

Breast Cancer Research and Treatment, Vol. 129, Iss. 1, 2011-08 ,pp. : 107-116

Springer Publishing Company

Access to resources Recommend Favorite

Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative Study

By                            

Experimental and Therapeutic Medicine, Vol. 3, Iss. 1, 2012-01 ,pp. : 60-65

Spandidos Publications

Access to resources Recommend Favorite

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer

By Roberts J.A.   Jenison E.L.   Kim K.   Clarke-Pearson D.   Langleben A.  

Gynecologic Oncology, Vol. 67, Iss. 2, 1997-11 ,pp. : 172-177

Elsevier

Access to resources Recommend Favorite

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

By Hu Zhihuang   Cheng Ying   Zhang Hongyu   Zhou Caicun   Han Baohui   Zhang Yiping   Huang Cheng   Chang Jianhua   Song Xiangqun   Liang Jun   Liang Houjie   Bai Chunxue   Yu Shiying   Chen Jia   Wang Jie   Pan Hongming   Chitkara Denesh   Hille Darcy   Zhang Li  

Supportive Care in Cancer, Vol. 22, Iss. 4, 2014-04 ,pp. : 979-987

Springer Publishing Company

Access to resources Recommend Favorite